Lucira Health creates battery-powered, single-use molecular diagnostic tests designed to deliver lab-quality results without requiring centralized instruments. Its lead product line includes an at-home influenza test that produces a text read-out within 20 minutes following a nasal swab. The company is also building a companion mobile application and telemedicine workflow so that consumers can seamlessly access follow-up care after receiving results. Earlier work with BARDA enabled Lucira to validate a clinical-use flu kit for CLIA-waived settings, and the new focus is converting that capability into an over-the-counter format for consumers. By targeting both healthcare providers and end users, Lucira aims to broaden access to rapid molecular testing and reduce time to treatment. No operating metrics, revenue figures, or user counts were disclosed in the article.

Total raised

$27M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2019